Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

Previous midterm follow-up reports after implantation of the Absorb everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-or...

Descripción completa

Detalles Bibliográficos
Autores: Katagiri, Yuki, Onuma, Yoshinobu, Asano, Taku, Iñiguez Romo, Andres, Jensen, Lisette Okkels, Cequier Fillat, Àngel R., Hofma, Sjoerd H., Christiansen, Evald H., Suttorp, Maarten, Brugaletta, Salvatore, Räber, Lorenz, Sabaté Tenas, Manuel, Windecker, Stephan, Serruys, Patrick W.
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/172268
Acceso en línea:https://hdl.handle.net/2445/172268
Access Level:acceso embargado
Palabra clave:Malalties coronàries
Infart de miocardi
Coronary diseases
Myocardial infarction
id ES_b83a4e53584fed93fb94213b294cf3f6
oai_identifier_str oai:recercat.cat:2445/172268
network_acronym_str ES
network_name_str España
repository_id_str
spelling Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)Katagiri, YukiOnuma, YoshinobuAsano, TakuIñiguez Romo, AndresJensen, Lisette OkkelsCequier Fillat, Àngel R.Hofma, Sjoerd H.Christiansen, Evald H.Suttorp, MaartenBrugaletta, SalvatoreRäber, LorenzSabaté Tenas, ManuelWindecker, StephanSerruys, Patrick W.Malalties coronàriesInfart de miocardiCoronary diseasesMyocardial infarctionPrevious midterm follow-up reports after implantation of the Absorb everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-oriented composite endpoint (DOCE: a composite of cardiac death, target vessel myocardial infarction [TVMI], and clinically driven target lesion revascularisation [CD-TLR])1. In contrast, in the six-month primary report of ABSORB STEMI: the TROFI II Study (NCT01986803)2, which randomised patients with ST-elevation myocardial infarction (STEMI) to receive either the Absorb BRS or the XIENCE metallic everolimus-eluting stent (EES; Abbott Vascular), optical frequency domain imaging (OFDI)-derived healing score was comparable between the BRS arm and the EES arm. The aim of this report was to present the three-year clinical outcome results of the BRS and the metallic EES at the time when full resorption of the scaffold device can be expected.EuroPCR and the European Association of Percutaneous Cardiovascular Interventions202020182020infoinfo:eu-repo/semantics/article1 p.application/pdfhttps://hdl.handle.net/2445/172268Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Ingléshttps://doi.org/10.4244/EIJ-D-18-00839Eurointervention, 2018, vol. 14, num. 11, p. e1224-e1226https://doi.org/10.4244/EIJ-D-18-00839(c) EuroPCR and the European Association of Percutaneous Cardiovascular Interventions, 2018info:eu-repo/semantics/embargoedAccessoai:recercat.cat:2445/1722682026-05-29T05:05:01Z
dc.title.none.fl_str_mv Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
title Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
spellingShingle Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
Katagiri, Yuki
Malalties coronàries
Infart de miocardi
Coronary diseases
Myocardial infarction
title_short Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
title_full Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
title_fullStr Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
title_full_unstemmed Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
title_sort Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
dc.creator.none.fl_str_mv Katagiri, Yuki
Onuma, Yoshinobu
Asano, Taku
Iñiguez Romo, Andres
Jensen, Lisette Okkels
Cequier Fillat, Àngel R.
Hofma, Sjoerd H.
Christiansen, Evald H.
Suttorp, Maarten
Brugaletta, Salvatore
Räber, Lorenz
Sabaté Tenas, Manuel
Windecker, Stephan
Serruys, Patrick W.
author Katagiri, Yuki
author_facet Katagiri, Yuki
Onuma, Yoshinobu
Asano, Taku
Iñiguez Romo, Andres
Jensen, Lisette Okkels
Cequier Fillat, Àngel R.
Hofma, Sjoerd H.
Christiansen, Evald H.
Suttorp, Maarten
Brugaletta, Salvatore
Räber, Lorenz
Sabaté Tenas, Manuel
Windecker, Stephan
Serruys, Patrick W.
author_role author
author2 Onuma, Yoshinobu
Asano, Taku
Iñiguez Romo, Andres
Jensen, Lisette Okkels
Cequier Fillat, Àngel R.
Hofma, Sjoerd H.
Christiansen, Evald H.
Suttorp, Maarten
Brugaletta, Salvatore
Räber, Lorenz
Sabaté Tenas, Manuel
Windecker, Stephan
Serruys, Patrick W.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malalties coronàries
Infart de miocardi
Coronary diseases
Myocardial infarction
topic Malalties coronàries
Infart de miocardi
Coronary diseases
Myocardial infarction
description Previous midterm follow-up reports after implantation of the Absorb everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-oriented composite endpoint (DOCE: a composite of cardiac death, target vessel myocardial infarction [TVMI], and clinically driven target lesion revascularisation [CD-TLR])1. In contrast, in the six-month primary report of ABSORB STEMI: the TROFI II Study (NCT01986803)2, which randomised patients with ST-elevation myocardial infarction (STEMI) to receive either the Absorb BRS or the XIENCE metallic everolimus-eluting stent (EES; Abbott Vascular), optical frequency domain imaging (OFDI)-derived healing score was comparable between the BRS arm and the EES arm. The aim of this report was to present the three-year clinical outcome results of the BRS and the metallic EES at the time when full resorption of the scaffold device can be expected.
publishDate 2018
dc.date.none.fl_str_mv 2018
2020
2020
info
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/172268
url https://hdl.handle.net/2445/172268
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.4244/EIJ-D-18-00839
Eurointervention, 2018, vol. 14, num. 11, p. e1224-e1226
https://doi.org/10.4244/EIJ-D-18-00839
dc.rights.none.fl_str_mv (c) EuroPCR and the European Association of Percutaneous Cardiovascular Interventions, 2018
info:eu-repo/semantics/embargoedAccess
rights_invalid_str_mv (c) EuroPCR and the European Association of Percutaneous Cardiovascular Interventions, 2018
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv 1 p.
application/pdf
dc.publisher.none.fl_str_mv EuroPCR and the European Association of Percutaneous Cardiovascular Interventions
publisher.none.fl_str_mv EuroPCR and the European Association of Percutaneous Cardiovascular Interventions
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417613194428416
score 15.812455

Similares en LA Referencia